Preclinical and Phase I/II Trials of AAV-AAT Vectors: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV1-CB-hAAT) Gene Vector to AAT-Deficient Adults

Trial Profile

Preclinical and Phase I/II Trials of AAV-AAT Vectors: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV1-CB-hAAT) Gene Vector to AAT-Deficient Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs AGTC 0106 (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 May 2016 Results published in the media release from American Society of Gene Therapy.
    • 05 May 2016 According to a media release from American Society of Gene Therapy, results from this trial were presented in a podium session at the American Society of Gene and Cell Therapy (ASGCT) 19th Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top